.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,786,111

« Back to Dashboard

Claims for Patent: 7,786,111

Title:Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract: A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s): Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim, DE), Schollenberger; Hermann (Ingelheim, DE), Pestel; Sabine (Attenweiler, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Warthausen, DE), Buettner; Frank (Attenweiler, DE), Heine; Claudia (Biberach, DE), Rudolf; Klaus (Warthausen, DE), Lustenberger; Philipp (Basel, CH), Hoenke; Christoph (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:12/258,830
Patent Claims: 1. A pharmaceutical composition comprising a compound of formula 1A ##STR00026## wherein: R.sup.1 is hydrogen, halogen, C.sub.1-C.sub.4-alkyl, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.4-alkyl or --O--C.sub.1-C.sub.4-alkyl; and R.sup.3 is methoxy, ethoxy, --O--CH.sub.2--COOH, --O--CH.sub.2--COOmethyl, or --O--CH.sub.2--COOethyl, or an acid addition salt thereof with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

2. The pharmaceutical composition according to claim 1, wherein R.sup.1 is hydrogen, fluorine, chlorine, methyl, or methoxy; and R.sup.2 is hydrogen, fluorine, chlorine, methyl, or methoxy.

3. The pharmaceutical composition according to claim 1, wherein: R.sup.1 is hydrogen or C.sub.1-C.sub.4-alkyl; and R.sup.2 is hydrogen or C.sub.1-C.sub.4-alkyl.

4. The pharmaceutical composition according to claim 1, wherein: R.sup.1 is hydrogen, methyl, or ethyl; and R.sup.2 is hydrogen, methyl, or ethyl.

5. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

6. A pharmaceutical composition comprising a compound of formula 1B ##STR00027## wherein: R.sup.1' is halogen, C.sub.1-C.sub.4-alkyl, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2' is halogen, C.sub.1-C.sub.4-alkyl or --O--C.sub.1-C.sub.4-alkyl; R.sup.3' is C.sub.1-C.sub.4-alkyl, halogen, or --O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

7. The pharmaceutical composition according to claim 6, wherein: R.sup.1' is fluorine, chlorine, methyl, or methoxy; R.sup.2' is fluorine, chlorine, methyl, or methoxy, and R.sup.3' is fluorine, chlorine, methyl, or methoxy.

8. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

9. A pharmaceutical composition comprising a compound of formula 1C ##STR00028## wherein: R.sup.1'' hydrogen, R.sup.2'' is hydrogen, fluorine, chlorine, or methyl; and R.sup.3'' is methyl, ethyl, isopropyl, tert-butyl, OH, fluorine, chlorine, bromine, methoxy, ethoxy, --O--CH.sub.2--COOH, --O--CH.sub.2--CH.sub.2--COOH, --O--CH.sub.2--CH.sub.2--CH.sub.2--COOH, --O--CH.sub.2--COO methyl, --O--CH.sub.2--COOethyl, --O--CH.sub.2--CH.sub.2--COO methyl, --O--CH.sub.2--CH.sub.2--COO ethyl, --O--CH.sub.2--CH.sub.2--CH.sub.2COO methyl, --O--CH.sub.2--CH.sub.2--CH.sub.2COO ethyl, or an acid addition salt thereof with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

10. The pharmaceutical composition according to claim 9, wherein: R.sup.1'' is hydrogen; R.sup.2'' is hydrogen, fluorine, chlorine, or methyl; and R.sup.3'' is OH, fluorine, chlorine, methyl, methoxy, ethoxy or O--CH.sub.2--COOH.

11. The pharmaceutical composition according to claim 9, wherein: R.sup.1'' and R.sup.2'' are each hydrogen.

12. The pharmaceutical composition according to claim 11, wherein R.sup.3'' is OH, fluorine, chlorine, methoxy, ethoxy or --O--CH.sub.2--COOH.

13. The pharmaceutical composition according to claim 12, wherein: R.sup.3'' is OH, fluorine, chlorine, methoxy or ethoxy.

14. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

15. A pharmaceutical composition comprising a compound selected from the group consisting of: (1) R-6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]et- hyl}-4H-benzo[1,4]oxazin-3-one; (2) R-6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyethylacetate)-1,1-dimethylethylam- ino]-ethyl}-4H-benzo[1,4]oxazin-3-one; (3) R-6-hydroxy-8-{1-hydroxy-2-[2-(4-phenoxyacetic acid)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one; (4) R-8-{2-[1,1-dimethyl-2-(2,4,6-trimethylphenyl)ethylamino]-1-hydroxyethyl}- -6-hydroxy-4H-benzo[1,4]oxazin-3-one; (5) R-6-hydroxy-8-{1-hydroxy-2-[2-(4-hydroxyphenyl)-1,1-dimethylethylamino]et- hyl}-4H-benzo[1,4]oxazin-3-one; (6) R-6-hydroxy-8-{1-hydroxy-2-[2-(4-isopropylphenyl)-1,1dimethylethylamino]e- thyl}-4H-benzo[1,4]oxazin-3-one; (7) R-8-{2-[2-(4-ethylphenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydro- xy-4H-benzo[1,4]oxazin-3-one; (8) R-8-{2-[2-(4-fluoro-3-methylphenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (9) R-8-{2-[2-(4-fluoro-2-methylphenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (10) R-8-{2-[2-(2,4-difluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one; (11) R-8-{2-[2-(3,5-difluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one; (12) R-8-{2-[2-(4-ethoxyphenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one; (13) R-8-{2-[2-(3,5-dimethylphenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one; (14) R-4-(4-{2-[2-hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-8- -yl)-ethylamino]-2-methylpropyl}phenoxy)butyric acid; (15) R-8-{2-[2-(3,4-difluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one; (16) R-8-{2-[2-(2-chloro-4-fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (17) R-8-{2-[2-(4-chlorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one; (18) R-8-{2-[2-(4-bromophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydro- xy-4H-benzo[1,4]oxazin-3-one; (19) R-8-{2-[2-(4-fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one; (20) R-8-{2-[2-(4-fluoro-3-methoxyphenyl)-1,1-dimethylethylamino]-1-hydroxyeth- yl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (21) R-8-{2-[2-(4-fluoro-2,6-dimethylphenyl)-1,1-dimethylethylamino]-1-hydroxy- ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (22) R-8-{2-[2-(4-chloro-2-methylphenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (23) R-8-{2-[2-(4-chloro-3-fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (24) R-8-{2-[2-(4-chloro-2-fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (25) R-8-{2-[2-(3-chloro-4-fluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (26) R-8-{2-[2-(2,6-difluoro-4-methoxyphenyl)-1,1-dimethylethylamino]-1-hydrox- yethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (27) R-8-{2-[2-(2,5-difluoro-4-methoxyphenyl)-1,1-dimethylethylamino]-1-hydrox- yethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (28) R-8-{2-[2-(4-fluoro-3,5-dimethylphenyl)-1,1-dimethylethylamino]-1-hydroxy- ethyl}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (29) R-8-{2-[2-(3,5-dichlorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one; (30) R-8-{2-[2-(4-chloro-3-methylphenyl)-1,1-dimethylethylamino]-1-hydroxyethy- l}-6-hydroxy-4H-benzo[1,4]oxazin-3-one; (31) R-8-{2-[2-(3,4,5-trifluorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}- -6-hydroxy-4H-benzo[1,4]oxazin-3-one; (32) R-8-{2-[2-(3-methylphenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-hydr- oxy-4H-benzo[1,4]oxazin-3-one; and (33) R-8-{2-[2-(3,4-dichlorophenyl)-1,1-dimethylethylamino]-1-hydroxyethyl}-6-- hydroxy-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

16. The pharmaceutical composition according to claim 15, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

17. A pharmaceutical composition comprising R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]- -ethyl}-4H-benzo[1,4]oxazin-3-one and a pharmaceutically acceptable excipient or carrier.

18. The pharmaceutical composition according to claim 17 comprising an acid addition salt of R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]- -ethyl}-4H-benzo[1,4]oxazin-3-one with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

19. The pharmaceutical composition according to claim 17, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

20. The pharmaceutical composition according to claim 18, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

21. A pharmaceutical composition comprising R-8-{2-[2-(2,4-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one and a pharmaceutically acceptable excipient or carrier.

22. The pharmaceutical composition according to claim 21 comprising an acid addition salt of R-8-{2-[2-(2,4-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

23. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

24. The pharmaceutical composition according to claim 22, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

25. A pharmaceutical composition comprising R-8-{2-[2-(3,5-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one and a pharmaceutically acceptable excipient or carrier.

26. The pharmaceutical composition according to claim 25 comprising an acid addition salt of the compound of R-8-{2-[2-(3,5-difluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-- 6-hydroxy-4H-benzo[1,4]oxazin-3-one with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

27. The pharmaceutical composition according to claim 25, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

28. The pharmaceutical composition according to claim 26, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

29. A pharmaceutical composition comprising R-8-{2-[2-(4-Ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-h- ydroxy-4H-benzo[1,4]oxazin-3-one and a pharmaceutically acceptable excipient or carrier.

30. The pharmaceutical composition according to claim 29, comprising an acid addition salt of the compound of R-8-{2-[2-(4-Ethoxy-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-h- ydroxy-4H-benzo[1,4]oxazin-3-one with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

31. The pharmaceutical composition according to claim 29, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

32. The pharmaceutical composition according to claim 30, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

33. A pharmaceutical composition comprising R-8-{2-[2-(4-fluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hy- droxy-4H-benzo[1,4]oxazin-3-one and a pharmaceutically acceptable excipient or carrier.

34. The pharmaceutical composition according to claim 33 comprising an acid addition salt of R-8-{2-[2-(4-fluorophenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hy- droxy-4H-benzo[1,4]oxazin-3-one with a pharmacologically acceptable acid, and a pharmaceutically acceptable excipient or carrier.

35. The pharmaceutical composition according to claim 33, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.

36. The pharmaceutical composition according to claim 34, wherein the pharmaceutical composition is an inhalable powder, propellant-containing metered-dose aerosol, or propellant-free inhalable solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc